IO Biotech, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 71.46 million compared to USD 67.88 million a year ago. Basic loss per share from continuing operations was USD 2.48 compared to USD 17.3 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.19 USD | -3.25% |
|
-9.16% | -36.70% |
May. 15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
May. 14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.70% | 78.4M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022